CN109929814A - Slow virus stabilizer and its application method - Google Patents
Slow virus stabilizer and its application method Download PDFInfo
- Publication number
- CN109929814A CN109929814A CN201910292252.9A CN201910292252A CN109929814A CN 109929814 A CN109929814 A CN 109929814A CN 201910292252 A CN201910292252 A CN 201910292252A CN 109929814 A CN109929814 A CN 109929814A
- Authority
- CN
- China
- Prior art keywords
- parts
- slow virus
- stabilizer
- weight
- slow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of slow virus stabilizer and its application method, the slow virus stabilizer includes the raw material of following parts by weight: pH buffers 1 part~20 parts of regulator, 20 parts~40 parts of human serum albumins, 1 part~15 parts and 50 parts~80 parts of polyethylene glycol of lipopolysaccharides.Slow virus stabilizer of the invention can be improved slow virus product in the stability of long-term preservation, and can keep the infectiousness of slow virus, can increase considerably the time of slow virus preservation, have good commercial promise.
Description
Technical field
The present invention relates to a kind of slow virus stabilizer and its application methods.
Background technique
Existing slow virus stabilizer usually needs that stabilizer is added during preservation, to guarantee the infection of slow virus
Property.But existing stabilizer standing time it is too long after can usually destroy the infectiousness of slow virus, lead to its stability significantly
Decline.It would therefore be highly desirable to which the communicable stabilizer of slow virus can be saved with long-time stable by researching and developing one kind.
Summary of the invention
An object of the present invention is to provide a kind of slow virus stabilizers.
A kind of slow virus stabilizer of the invention, the raw material including following parts by weight: pH buffers regulator 1 part~20
Part, 20 parts~40 parts of human serum albumins, 1 part~15 parts and 50 parts~80 parts of polyethylene glycol of lipopolysaccharides.
Slow virus stabilizer of the invention can be improved slow virus product in the stability of long-term preservation, and can keep
The infectiousness of slow virus can increase considerably the time of slow virus preservation, have good commercial promise.
In addition, the slow virus stabilizer that the present invention is above-mentioned, can also have the following additional technical features:
As a preferred embodiment of the present invention, the slow virus stabilizer, the raw material including following parts by weight: pH
1 part of regulator of buffering, 40 parts of human serum albumins, 1 part and 80 parts of polyethylene glycol of lipopolysaccharides.
As a preferred embodiment of the present invention, the slow virus stabilizer, the raw material including following parts by weight: pH
20 parts of regulator of buffering, 20 parts of human serum albumins, 15 parts and 50 parts of polyethylene glycol of lipopolysaccharides.
As a preferred embodiment of the present invention, the slow virus stabilizer, the raw material including following parts by weight: pH
10 parts of regulator of buffering, 30 parts of human serum albumins, 7 parts and 65 parts of polyethylene glycol of lipopolysaccharides.
As a preferred embodiment of the present invention, the slow virus stabilizer, the raw material including following parts by weight: pH
5 parts of regulator of buffering, 35 parts of human serum albumins, 3 parts and 72 parts of polyethylene glycol of lipopolysaccharides.
As a preferred embodiment of the present invention, the slow virus stabilizer, the raw material including following parts by weight: pH
15 parts of regulator of buffering, 25 parts of human serum albumins, 12 parts and 57 parts of polyethylene glycol of lipopolysaccharides.
As a preferred embodiment of the present invention, the slow virus stabilizer, the raw material including following parts by weight: institute
It states pH buffering regulator and includes at least one of citric acid, potassium citrate, lactic acid and tartaric acid.
It is another object of the present invention to the application methods for proposing the slow virus stabilizer.
The application method of the slow virus stabilizer includes the following steps: that slow virus supernatant is concentrated into original first
The 1/3~1/2 of weight, then by slow virus supernatant concentrated liquor and the slow virus stabilizer according to weight ratio be 1:(1.5~
2.5) it is saved at a temperature of -80 DEG C~4 DEG C after mixing.
Another object of the present invention is to propose application of the slow virus stabilizer in slow virus saves.
Additional aspect and advantage of the invention will be set forth in part in the description, and will partially become from the following description
Obviously, or practice through the invention is recognized.
Specific embodiment
The embodiment of the present invention is described below in detail, the embodiment is exemplary, it is intended to it is used to explain the present invention, and
It is not considered as limiting the invention.
Embodiment 1
Embodiment 1 proposes a kind of slow virus stabilizer, the raw material including following parts by weight: 1 part of citric acid, human serum
40 parts of albumin, 1 part and 80 parts of polyethylene glycol of lipopolysaccharides.
The application method of the slow virus stabilizer of embodiment 1 includes the following steps: first to be concentrated into slow virus supernatant
Then slow virus supernatant concentrated liquor is after 1:2.5 is mixed according to weight ratio with the slow virus stabilizer by the 1/3 of original weight amount
It is saved at a temperature of -80 DEG C.
Embodiment 2
Embodiment 2 proposes a kind of slow virus stabilizer, the raw material including following parts by weight: 20 parts of tartaric acid, people's blood
Pure protein 20 part, 15 parts and 50 parts of polyethylene glycol of lipopolysaccharides.
The application method of the slow virus stabilizer of embodiment 2 includes the following steps: first to be concentrated into slow virus supernatant
Then slow virus supernatant concentrated liquor is after 1:1.5 is mixed according to weight ratio with the slow virus stabilizer by the 1/2 of original weight amount
It is saved at a temperature of 4 DEG C.
Embodiment 3
Embodiment 3 proposes a kind of slow virus stabilizer, the raw material including following parts by weight: 10 parts of lactic acid, human serum
30 parts of albumin, 7 parts and 65 parts of polyethylene glycol of lipopolysaccharides.
The application method of the slow virus stabilizer of embodiment 3 includes the following steps: first to be concentrated into slow virus supernatant
Then slow virus supernatant concentrated liquor is after 1:2 is mixed according to weight ratio with the slow virus stabilizer by the 1/3 of original weight amount
It is saved at a temperature of -40 DEG C.
Embodiment 4
Embodiment 4 proposes a kind of slow virus stabilizer, the raw material including following parts by weight: 5 parts of potassium citrate, people's blood
35 parts of pure albumen, 3 parts and 72 parts of polyethylene glycol of lipopolysaccharides.
The application method of the slow virus stabilizer of embodiment 4 includes the following steps: first to be concentrated into slow virus supernatant
Then slow virus supernatant concentrated liquor is after 1:1.8 is mixed according to weight ratio with the slow virus stabilizer by the 1/2 of original weight amount
It is saved at a temperature of -60 DEG C.
Embodiment 5
Embodiment 5 proposes a kind of slow virus stabilizer, the raw material including following parts by weight: 15 parts of citric acid, people's blood
Pure protein 25 part, 12 parts and 57 parts of polyethylene glycol of lipopolysaccharides.
The application method of the slow virus stabilizer of embodiment 5 includes the following steps: first to be concentrated into slow virus supernatant
Then slow virus supernatant concentrated liquor is after 1:2.3 is mixed according to weight ratio with the slow virus stabilizer by the 1/3 of original weight amount
It is saved at a temperature of -20 DEG C.
To sum up, slow virus product can be improved in the stability of long-term preservation in slow virus stabilizer of the invention, and can be with
The infectiousness for keeping slow virus can increase considerably the time of slow virus preservation, have good commercial promise.
In the description of this specification, reference term " one embodiment ", " some embodiments ", " example ", " specifically show
The description of example " or " some examples " etc. means specific features, structure, material or spy described in conjunction with this embodiment or example
Point is included at least one embodiment or example of the invention.In the present specification, schematic expression of the above terms are not
It must be directed to identical embodiment or example.Moreover, particular features, structures, materials, or characteristics described can be in office
It can be combined in any suitable manner in one or more embodiment or examples.In addition, without conflicting with each other, the skill of this field
Art personnel can tie the feature of different embodiments or examples described in this specification and different embodiments or examples
It closes and combines.
Although the embodiments of the present invention has been shown and described above, it is to be understood that above-described embodiment is example
Property, it is not considered as limiting the invention, those skilled in the art within the scope of the invention can be to above-mentioned
Embodiment is changed, modifies, replacement and variant.
Claims (9)
1. a kind of slow virus stabilizer, which is characterized in that the raw material including following parts by weight: pH buffers regulator 1 part~20
Part, 20 parts~40 parts of human serum albumins, 1 part~15 parts and 50 parts~80 parts of polyethylene glycol of lipopolysaccharides.
2. slow virus stabilizer according to claim 1, which is characterized in that the raw material including following parts by weight: pH is slow
Rush 1 part of regulator, 40 parts of human serum albumins, 1 part and 80 parts of polyethylene glycol of lipopolysaccharides.
3. slow virus stabilizer according to claim 1, which is characterized in that the raw material including following parts by weight: pH is slow
Rush 20 parts of regulator, 20 parts of human serum albumins, 15 parts and 50 parts of polyethylene glycol of lipopolysaccharides.
4. slow virus stabilizer according to claim 1, which is characterized in that the raw material including following parts by weight: pH is slow
Rush 10 parts of regulator, 30 parts of human serum albumins, 7 parts and 65 parts of polyethylene glycol of lipopolysaccharides.
5. slow virus stabilizer according to claim 1, which is characterized in that the raw material including following parts by weight: pH is slow
Rush 5 parts of regulator, 35 parts of human serum albumins, 3 parts and 72 parts of polyethylene glycol of lipopolysaccharides.
6. slow virus stabilizer according to claim 1, which is characterized in that the raw material including following parts by weight: pH is slow
Rush 15 parts of regulator, 25 parts of human serum albumins, 12 parts and 57 parts of polyethylene glycol of lipopolysaccharides.
7. slow virus stabilizer according to claim 1-6, which is characterized in that the pH buffering regulator is at least
Including one of citric acid, potassium citrate, lactic acid and tartaric acid.
8. the application method of the described in any item slow virus stabilizers of claim 1-7, which comprises the steps of:
Slow virus supernatant is concentrated into the 1/3~1/2 of original weight amount first, then by slow virus supernatant concentrated liquor and the slow virus
Stabilizer is 1:(1.5~2.5 according to weight ratio) it saves at a temperature of -80 DEG C~4 DEG C after mixing.
9. application of the described in any item slow virus stabilizers of claim 1-8 in slow virus saves.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910292252.9A CN109929814A (en) | 2019-04-12 | 2019-04-12 | Slow virus stabilizer and its application method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910292252.9A CN109929814A (en) | 2019-04-12 | 2019-04-12 | Slow virus stabilizer and its application method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109929814A true CN109929814A (en) | 2019-06-25 |
Family
ID=66989824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910292252.9A Pending CN109929814A (en) | 2019-04-12 | 2019-04-12 | Slow virus stabilizer and its application method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109929814A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107312799A (en) * | 2017-06-30 | 2017-11-03 | 深圳宾德生物技术有限公司 | Slow virus carrier freezes protection liquid and its preparation method and application |
| CN108624505A (en) * | 2018-08-29 | 2018-10-09 | 上海比昂生物医药科技有限公司 | A kind of slow virus freezing drying protective agent and slow virus freeze-dried powder |
-
2019
- 2019-04-12 CN CN201910292252.9A patent/CN109929814A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107312799A (en) * | 2017-06-30 | 2017-11-03 | 深圳宾德生物技术有限公司 | Slow virus carrier freezes protection liquid and its preparation method and application |
| CN108624505A (en) * | 2018-08-29 | 2018-10-09 | 上海比昂生物医药科技有限公司 | A kind of slow virus freezing drying protective agent and slow virus freeze-dried powder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA518400335B1 (en) | Chimeric Neurotoxins | |
| BR9713521A (en) | ||
| NO872932L (en) | PROCEDURE FOR THE MANUFACTURE OF PROTEINS WITH FACTOR VIVILITY BY MICROBIAL HOSTS, EXPRESSING VECTORS, HOSTING CELLS, ANTIBIOTICS. | |
| MX2023001595A (en) | Fusion proteins comprising milk proteins and compositions thereof. | |
| SE0300949D0 (en) | Instant powder composition | |
| DE602006010740D1 (en) | RECOMBINANT GELATINE PARTICLES FOR CELL ADHESION | |
| US8278270B2 (en) | HGF precursor protein variant and active protein thereof | |
| WO2021003469A3 (en) | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same | |
| CN109929814A (en) | Slow virus stabilizer and its application method | |
| HK1077074A1 (en) | Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof | |
| WO2018115509A3 (en) | New flavivirus vaccine | |
| WO2020167455A3 (en) | Platform for producing glycoproteins, identifying glycosylation pathways | |
| Muller-Steffner et al. | Identification of the N-glycosylation sites on recombinant bovine CD38 expressed in Pichia pastoris: their impact on enzyme stability and catalytic activity | |
| Shelikoff et al. | The effect of protein synthesis inhibitors on the glycosylation site occupancy of recombinant human prolactin | |
| WO2021072129A8 (en) | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins | |
| ATE386054T1 (en) | GLYCOSYLATED HUMAN INTERFERON ALPHA ISOFORM | |
| WO2022023538A3 (en) | Serum half-life extended pd-l1 inhibitory polypeptides | |
| WO2020010117A3 (en) | Fgf21 formulations | |
| CN110012899A (en) | Cell RNA stabilizer and its application method | |
| CN110346559A (en) | A kind of freeze-dried type measurement PT preparation method of reagent thereof | |
| BR112019004337A2 (en) | isolated peptide, isolated polypeptide, method for modifying a peptide, isolated nucleic acid, genetic construct, cell, methods of producing an agent, promoting cell proliferation and wound healing, agent, pharmaceutical composition and antibody | |
| WO2022016188A3 (en) | Engineered n-glycosyltransferases with altered specificities | |
| Takahashi | Anomalous proteins associated with three strains of tobacco mosaic virus | |
| Ngong | Understanding of African Christianity: African Identity and the Triune God | |
| WO2020076987A3 (en) | Engineered fibroblast growth factor variants as receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Shao Yue Inventor after: Fu Jiangang Inventor after: Jiang Taohua Inventor before: Fu Jiangang Inventor before: Shao Yue Inventor before: Jiang Taohua |
|
| CB03 | Change of inventor or designer information |